Werner's Syndrome Clinical Trial
Verified date | July 2004 |
Source | Office of Rare Diseases (ORD) |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Federal Government |
Study type | Interventional |
OBJECTIVES:
I. Assess the safety and efficacy of recombinant human insulin-like growth factor 1 in a
patient with Werner's syndrome and osteoporosis.
Status | Completed |
Enrollment | 1 |
Est. completion date | |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A and older |
Eligibility |
PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Werner's syndrome with osteoporosis and low serum insulin-like growth factor 1 level Patient treated on protocol 04-9215300 "Metabolic and Skeletal Effects of Exogenous Recombinant Human Insulin-Like Growth Factor" |
Allocation: Non-Randomized, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
National Center for Research Resources (NCRR) | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), University of Texas |